Product Disease Areas

We are focused on the development of IVD products for Autoimmune Diseases, specifically in the areas of:

Therapeutic challenges for autoimmune diseases

Although existing therapies for autoimmune diseases have improved patient treatment over the last decade, many of these drugs have been shown to be active in less than 50% of patients. As autoimmune diseases are chronic conditions, the treatment success or failure is often seen after lengthy treatment cycles, sometimes in excess of 6 months. This is not only expensive to the healthcare provider but also increases the likelihood of those patients developing irreversible tissue and organ damage. Consequently, there is a real need to develop diagnostic solutions that allow clinicians to make better treatment selections for autoimmune diseases, both for current marketed drugs, and for novel drugs in clinical development.

It is widely acknowledged that autoimmune diseases are complex conditions that require sophisticated patient stratification tools to define sub-groups within the population and determine which patients will respond to a certain drug.

Complex conditions require a different approach

The identification of patient subgroups has become essential for developing medicines that target smaller numbers of patients, and work effectively for each individual. In addition, the repositioning of marketed drugs according to response rates or side effects is a key industry initiative that is supported by clinicians, patients and regulatory bodies alike.

At Protagen, our understanding of disease-specific autoantibody profiles and their application to novel, robust diagnostic test development, means that we are exceptionally well positioned to create products which will improve the diagnosis and subsequent treatment of autoimmune disease.

Contact us

Rheumatoid Arthritis (RA)

Rheumatoid arthritis (RA) is a common, archetypal autoimmune disease that results in a chronic, systemic inflammatory disorder and occurs in about 1% of the adult population.

Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus (SLE) is clinically and serologically the most diverse systemic autoimmune disease and is currently incurable.

Multiple Sclerosis (MS)

Multiple Sclerosis (MS) is a chronic, inflammatory autoimmune condition in which the immune system attacks the central nervous system.

Autoimmune Disease Services

stratified man

Protagen has established a strong pipeline of tools to enable pharma co-development services within the field of autoimmune disease research.

Ankylosing Spondylitis (AS)

Ankylosing spondylitis (AS) is the second most common type of chronic inflammatory arthritis and is characterized by pathologic new bone formation that ultimately affects bones, muscles and ligaments.

Systemic Sclerosis (SSc)

Systemic sclerosis (SSc) is an autoimmune disease of the connective tissue.

Neuromyelitis Optica (NMO)

Clinically, NMO presents with severe relapsing attacks of inflammation and demyelination of the optic nerve (optic neuritis) and the spinal cord (myelitis), often characterized with poor or no recovery from resulting disabilities.